ArticleJournal of surgical case reports2025
Harnessing immunotherapy in sporadic MSI-H/dMMR colorectal cancer: a case study.
Article in Journal of surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes Following Colorectal Cancer Resection in Elderly Patients.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a prevalent malignancy, with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors representing a distinct, immunogenic subset. These tumors respond poorly to conventional chemotherapy but demonstrate favorable outcomes with immune checkpoint inhibitors (ICIs). We report the case of a 90-year-old male with severe anemia and a newly diagnosed sporadic MSI-H/dMMR CRC characterized by poorly differentiated, mucinous, and signet ring cell features. Molecular profiling revealed MLH1/PMS2 loss and MLH1 promoter hypermethylation. Despite his advanced age and multiple comorbidities, the patient underwent surgical resection followed by referral for ICI therapy in lieu of cytotoxic chemotherapy. This case highlights the importance of molecular testing in guiding treatment decisions and supports the consideration of ICIs in select elderly patients. It emphasizes that age alone should not preclude the use of effective, personalized therapies in CRC, particularly in those with good functional status and biomarkers predictive of immunotherapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.